Product Description
Remimazolam, a novel benzodiazepine created out of so-called soft drug development, is an ultrashort-acting intravenous sedative-hypnotic currently being investigated in clinical trials. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27496519/)
Mechanisms of Action: GABA Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Sweden | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Jiangsu Hengrui Medicine Co
Company Location: Asia Pacific
Company Founding Year: 1970
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Denmark, South Korea, United States
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Healthy Volunteers|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07036419 |
HR7056-207 | P3 |
Recruiting |
Other |
2026-05-01 |
14% |
2026-02-19 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT05913336 |
HR7056-206 | P2 |
Completed |
Other |
2025-03-05 |
12% |
2025-09-04 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
CTR20231807 |
CTR20231807 | P2 |
Completed |
Unknown |
2025-03-05 |
2025-09-07 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20213129 |
CTR20213129 | P2 |
Completed |
Unknown |
2023-04-19 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT05152303 |
HR7056-205 | P2 |
Completed |
Other |
2023-04-02 |
12% |
2023-05-25 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT04851717 |
DA10030 | P3 |
Active, not recruiting |
Other |
2027-10-01 |
24% |
2025-07-02 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2020-004118-37 |
2020-004118-37 | P3 |
Active, not recruiting |
Other |
2025-02-28 |
|||
NCT06222294 |
HR7056-302 | P3 |
Completed |
Other |
2024-08-13 |
15% |
2025-08-27 |
|
ACTRN12621001702808p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Healthy Volunteers |
2022-03-25 |
|||
NCT05836545 |
NCT05836545 | P3 |
Completed |
Healthy Volunteers |
2024-01-06 |
2025-11-19 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/14/2026 |
News Article |
Eagle Pharmaceuticals Announces Divestiture of Barhemsys |
|
10/21/2025 |
News Article |
Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders |
|
10/06/2025 |
News Article |
Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements |
|
09/17/2025 |
News Article |
Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years |